Business Context and Reporting Period
NanoViricides, Inc. (NNVC) is a clinical-stage nano-biopharmaceutical company focused on developing broad-spectrum antiviral nanomedicines. The company operates a cGMP-compliant manufacturing facility in Shelton, Connecticut. This Form 10-Q covers the quarterly period ended September 30, 2024. The company's lead drug candidate, NV-387, has completed a Phase Ia/Ib safety and tolerability trial with no reported adverse events and is advancing toward Phase II trials for Respiratory Syncytial Virus (RSV) and MPox.
Key Financial Metrics
| Metric | Q1 2024 (Ended Sept 30) | Q1 2023 (Ended Sept 30) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,126,811) | $(1,968,746) |
| Net Loss Per Share (Basic & Diluted) | $(0.23) | $(0.17) |
| Operating Expenses | $3,167,834 | $2,031,591 |
| Research & Development (R&D) | $1,933,091 | $1,466,665 |
| General & Administrative (G&A) | $1,234,743 | $564,926 |
| Cash and Cash Equivalents (End of Period) | $3,866,289 | $6,969,823 |
| Net Cash Used in Operating Activities | $(2,594,863) | $(1,171,694) |
| Total Current Liabilities | $1,632,706 | $1,358,776 |
| Stockholders' Equity | $10,107,791 | $12,968,510 |
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by approximately $1.16 million (59%) compared to the prior year quarter, driven by higher operating expenses.
- R&D Expenses: Increased by $466,426 (32%) primarily due to increased laboratory fees and non-clinical studies required to advance NV-387 into Phase II.
- G&A Expenses: Increased by $699,817 (124%) largely due to professional fees associated with investor outreach activities.
- Cash Position: Cash and cash equivalents decreased by approximately $931,000 during the quarter, resulting in a net cash burn of $2.6 million from operations.
- Interest Income: Decreased by $58,315 due to lower average cash balances.
- Interest Expense: Decreased to $0 from $36,493 in the prior year as accrued interest on a related-party convertible note was cancelled and converted to equity in the prior fiscal year.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Clinical Progress: The company is preparing regulatory documentation for Phase II clinical trials of NV-387 for RSV (pediatric focus) and MPox (under WHO MEURI protocol). The Phase I trial for NV-387 (oral syrup and gummies) concluded with no adverse events.
- Manufacturing: The company has scaled up cGMP manufacturing of NV-387, doubling batch sizes to prepare for Phase II supply.
- Strategic Shift: Due to the lack of available COVID-19 patients for enrollment, the company closed the patient cohort of its Phase 1a/1b COVID trial in April 2024. Resources are now focused on RSV and MPox indications.
- Capital Raising: The company utilized an "At-The-Market" (ATM) facility to raise approximately $1.71 million during the quarter. Subsequent to the quarter end (Oct 1 - Nov 7, 2024), an additional $631,000 was raised via ATM sales.
Risks and Contingencies
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for at least 12 months from the filing date. Current cash ($3.9M) plus recent ATM proceeds and a $3M line of credit (undrawn) are deemed insufficient to fund planned operations.
- Related Party Dependence: The company relies heavily on TheraCour Pharma, Inc. (owned by CEO Dr. Anil Diwan) for technology licensing, R&D services, and manufacturing support. Accounts payable to TheraCour totaled $636,550 as of September 30, 2024.
- Financing Needs: The company must secure additional equity or debt financing, non-dilutive grants, or partnership agreements to fund future clinical trials and operations.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $3.9M cash balance plus the $3M line of credit against the projected burn rate for Phase II trials.
- Related Party Transactions: Review the terms of the license agreements and service fees with TheraCour Pharma, Inc., which accounts for a significant portion of R&D costs and accounts payable.
- Phase II Timeline: Confirm the regulatory status and expected start dates for the RSV and MPox Phase II trials, as these are critical milestones for future funding.
- ATM Utilization: Monitor the remaining capacity under the $50M ATM agreement and the pricing of recent share sales to assess dilution risks.
- Intellectual Property: Confirm the status of patent applications (PCT/US21/39050 and PCT/US22/35210) and the exclusivity of the licenses held from TheraCour.